Pre-Screening Study to Identify MTAP Loss in Advanced Solid Tumors or Lymphoma

Study AG270-PS-001 is a pre-screening study to identify subjects with advanced solid tumors
or lymphoma in which the MTAP protein has been lost. Subjects whose tumor tissue has lost the
MTAP protein may be considered for future enrollment into a Phase 1 clinical study of an
experimental drug, AG-270, that is designed to inhibit the growth of tumors lacking this
protein.

Identification of the loss of MTAP will rely solely on the evaluation of archival tumor
tissue samples by IHC. This study is therefore non-interventional

Inclusion Criteria:

1. Be ≥18 years of age.

2. Have a histologically confirmed diagnosis of an advanced solid tumor (other than a
primary CNS malignancy) or lymphoma.

3. Have archival tumor tissue that can be provided for assessment of MTAP deletion
status.

4. Have given written informed consent to participate in this study.

Exclusion Criteria:

1. Have a primary CNS malignancy (eg, GBM).

2. Have a medical or psychological condition deemed by the Investigator likely to
interfere with the subject's ability to give informed consent or participate in the
study.